Omnitura 2500 iStock_000019408736_Large.jpg
Omnitura 2500 iStock_000050664932_Large copy.jpg
Omnitura 2500 iStock_000019408736_Large.jpg

WE ARE OMNITURA


Omnitura Therapeutics is a biopharmaceutical company commercializing a new class of Omnivalent Immuno-Oncology Therapy designed to address the Fundamental Complexity of Cancer and Comorbid Chronic Diseases with a Whole Systems Biology Approach.

SCROLL DOWN

WE ARE OMNITURA


Omnitura Therapeutics is a biopharmaceutical company commercializing a new class of Omnivalent Immuno-Oncology Therapy designed to address the Fundamental Complexity of Cancer and Comorbid Chronic Diseases with a Whole Systems Biology Approach.

OMNIVALENT: THE KEY TO NEXT GENERATION CANCER TREATMENT

We are focused on developing omnivalent immuno-oncology drugs capable of regulating, not blocking, multiple molecular pathways, in order to kill different cancer cell sub-types as well as reboot the immune system, all while providing patients with good quality of life. Our lead drug candidate Aneustat™ is expected to be the 1st oncology drug without toxicity, side effects or drug resistance.

Omnitura 2500 iStock_000050664932_Large copy.jpg

OUR MISSION


Omnitura's vision is to make cancer a manageable chronic disease - a disease we live with, while enjoying good quality life, rather than die from. It is envisioned that the Omnitura solution may ultimately reduce the incidence of cancer.

OUR MISSION


Omnitura's vision is to make cancer a manageable chronic disease - a disease we live with, while enjoying good quality life, rather than die from. It is envisioned that the Omnitura solution may ultimately reduce the incidence of cancer.

A PARADIGM SHIFT IS HAPPENING

The next generation of cancer drug development will be capable of disrupting numerous molecular pathways associated with cancer, all while empowering the body's own immune systemOmnitura is positioned to be a leader in this new omnivalent drug development paradigm. It all starts with Aneustat™.